Wells Fargo & Company Mersana Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding MRSN
# of Institutions
124Shares Held
114MCall Options Held
73.5KPut Options Held
46.4K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$41.1 Million1.38% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$24 Million2.5% of portfolio
-
Nextech Invest Ag9.53MShares$20.2 Million3.61% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$18.4 Million3.56% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$17.8 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $206M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...